Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression a

Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions

INDIANAPOLIS, Sept. 11, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of AtaiBeckley Inc. AtaiBeckley is a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions, including

https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-ataibeckley-advance-therapies investor.lilly.com

RSS Hunter • Sep 11